CRISPR Therapeutics AG (CRSP) Research & Development (2015 - 2026)

CRISPR Therapeutics AG has disclosed Research & Development across 12 years of filings, most recently posting $68.6 million for Q1 2026.

• Research & Development for Q1 2026 came in at $68.6 million, down 5.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $210.4 million (down 31.37% YoY), and the FY2025 annual result was $284.8 million, down 8.2% from the prior year.
• Research & Development came in at $68.6 million for Q1 2026 at CRISPR Therapeutics AG, up from $13.0 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $123.2 million in Q2 2022 to a low of $13.0 million in Q4 2025.
• The 5-year median for Research & Development is $82.2 million (2024), against an average of $84.8 million.
• Across the five-year window, Research & Development jumped 67.44% in 2022 and plunged 81.88% in 2025, its largest moves.
• CRISPR Therapeutics AG's Research & Development stood at $103.6 million in 2022, then decreased by 8.12% to $95.1 million in 2023, then fell by 24.6% to $71.7 million in 2024, then slumped by 81.88% to $13.0 million in 2025, then surged by 427.49% to $68.6 million in 2026.
• The last three Research & Development figures came in at $68.6 million (Q1 2026), $13.0 million (Q4 2025), and $58.9 million (Q3 2025), per Business Quant data.